Format

Send to

Choose Destination
Dermatology. 2018 Nov 8:1-10. doi: 10.1159/000492784. [Epub ahead of print]

Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients.

Author information

1
Department of Dermatology, Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
2
Department of Dermatology, Laishan Branch of Yantai Yuhuangding Hospital, Yantai, China.
3
Department of Dermatology, Seventh People's Hospital of Shanghai University of TCM, Shanghai, Chinaduanyanjuan@aliyun.com.

Abstract

BACKGROUND/AIMS:

This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients.

METHODS:

A total of 85 psoriasis patients who received 6 months of etanercept treatment were consecutively enrolled in this prospective cohort study. The Psoriasis Area and Severity Index (PASI) score was evaluated at month 0 (M0), M1, M3, and M6, and the corresponding PASI 75/90 response at each visit was assessed. Also, anxiety and depression symptoms were assessed by the Hospital Anxiety and Depression Scale (HADS) at M0, M1, M3, and M6.

RESULTS:

Depression symptoms were observed to correlate with female gender (p = 0.004), longer disease duration (p = 0.018), and higher PASI score (p < 0.001), and anxiety symptoms were seen to be associated with female gender (p = 0.017), larger psoriasis-affected body surface area (p = 0.049), and higher PASI score (p = 0.017) in psoriasis patients. After etanercept treatment, HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores were both decreased at M1, M3, and M6 (all p < 0.001) compared with M0. Most importantly, baseline depressed patients presented with a lower PASI 75 response rate at M3 (p = 0.014) and M6 (p = 0.005), and a reduced PASI 90 response rate at M6 (p = 0.045) compared with baseline non-depressed patients. Furthermore, multivariate logistic regression analyses revealed that depression symptoms at baseline were an independent predictive factor for the lower possibility of both PASI 75 response (p = 0.048) and PASI 90 response (p = 0.048) achievements at M6 in psoriasis patients. However, no correlation of baseline anxiety symptoms with PASI 75/90 responses was observed.

CONCLUSION:

Depression symptoms at baseline independently predict a worse clinical response to etanercept treatment in psoriasis patients.

KEYWORDS:

Anxiety; Depression; Etanercept; Psoriasis; Response

PMID:
30408786
DOI:
10.1159/000492784

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center